Vaughn Embro-Pantalony
Chairman
Marc Rubin
Director
Susan Hicks
Director
Camille Belliveau
Director
Jack Stewart
Chief Scientific Officer & Director
Paul Gunn
President
Robert Bruce
Chief Executive Officer
Robert is CEO of Soricimed and responsible for leading the company’s day-to-day operations, driving its go-forward strategy, managing relationships with key industry stakeholders and undertaking major capital raise efforts. Robert brings over 30 years of experience leading companies in the professional services, technology, life sciences and manufacturing sectors along with domestic, U.S. and international merger & acquisitions experience. Robert has received CA and CPA designations.
Jack Stewart
Chief Scientific Officer & Director
Jack is a founder of Soricimed which was created following his discoveries while researching the paralytic toxins of shrew venom. As the current Chief Scientific Officer, he has directed the development of Soricimed’s R&D effort from an early-stage start-up to a clinical stage company. Jack was previously the President and CEO of Soricimed and is a Professor Emeritus of Biochemistry at Mount Allison University. He has been published in several international peer-reviewed journals and encyclopedia.
Paul Gunn
President
Frank Michalargias
Chief Financial Officer
Frank is Chief Financial Officer for Soricimed bringing vast experience leading financial operations for publicly-traded companies across North American over the past 30 years. He recently served as CFO for Canadian companies Helix BioPharma Corporation, AP Plasman Corporation and CFM Corporation. In his current role, Frank manages financial operations, maintains strict fiscal control and utilizes technologies to enhance operations and support Soricimed in its research and development efforts.
Bob Cory
Vice President, Business Development
Bob is Vice-President, Business Development for Soricimed responsible for formulating, implementing and managing the corporate partnering strategy. He brings 25+ years of experience in business development for biotechnology companies across a range of therapeutic and diagnostic areas. Bob holds an MBA from Wilfred Laurier University, a PhD in Biochemistry and Molecular Biology from Waterloo University and was a Postdoctoral Fellow at the Ontario Veterinary College.
Dominique Dugourd
Vice President Research & Development
Dominique is the Vice-President of Research & Development for Soricimed bringing over 20 years of experience in the pharmaceutical and medical devices industries along with in-depth knowledge and experience of research and development of drug products from the bench to the clinic – IND/CTA, Phase 1 to Phase 3 pivotal trials including the filing of an FDA pre-NDA. Dominique has a PhD in Microbiology and Immunology from the University of Montreal.
Tyler Lutes
Senior Scientist
Tyler is a Senior Scientist for Soricimed who leads planning and proposing of projects and experiments – notably the development of the company’s novel peptide platform and its oncology applications. He manages day-to-day workflow and develops protocols and reports for Soricimed’s R&D division. Tyler is a molecular biologist and biochemist bringing over 15 years of research experience in clinical and pre-clinical drug development employing a variety of molecular, biochemical and analytical techniques.
Sam Magee
Financial Analyst
Alison Cudmore
Scientist
Alison is a scientist at Soricimed supporting development of the company’s novel peptide platform and its potential as an oncology therapy. She joined Soricimed from the Ottawa Hospital Research Institute, where she focused her graduate research towards characterizing the impact of specific tumour mutations on the efficacy of oncolytic viruses for the treatment of ovarian cancer. Alison holds a Masters in Microbiology & Immunology and an Honours BSc. in Biomedical Science from the University of Ottawa.
| 
| 
| 
Address
18 Botsford St., Suite 201
Moncton, N.B. E1C 4W7
Canada
T: 506.856.0400
F: 506.856.0414
E: info@soricimed.com
© Copyright 2022 Innovasium Soricimed Biopharma